Stockreport

TapImmune's T-cell vaccine candidate TPIV200 shows encouraging action in early-stage cancer study; shares ahead 16% premarket [Seeking Alpha]

TAPIMMUNE INC COMMON  (TPIV) 
NASDAQ:AMEX Investor Relations: tapimmune.com/investors
PDF TapImmune's T-cell vaccine candidate TPIV200 shows encouraging action in early-stage cancer study; shares ahead 16% premarketThinly traded nano cap TapImmune (NASDAQ:TPI [Read more]